

Francesco Leone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/202101/publications.pdf>

Version: 2024-02-01

109
papers

4,011
citations

196777

29
h-index

145109

60
g-index

112
all docs

112
docs citations

112
times ranked

6517
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. <i>Journal of Gastrointestinal Cancer</i> , 2022, 53, 289-298.	0.6	6
2	Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. <i>Journal of Chemotherapy</i> , 2022, 34, 123-132.	0.7	1
3	Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 771418.	1.3	4
4	A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient. <i>Cancers</i> , 2021, 13, 2051.	1.7	8
5	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. <i>Journal of Gastrointestinal Cancer</i> , 2021, , 1.	0.6	0
6	A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy. <i>Acta OncolÃ³gica</i> , 2021, 60, 1317-1324.	0.8	2
7	The prognostic nutritional index predicts survival and response to firstâ€line chemotherapy in advanced biliary cancer. <i>Liver International</i> , 2020, 40, 704-711.	1.9	42
8	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , 2020, 5, e000911.	2.0	94
9	Radiomics predicts response of individual <scp>HER2</scp>â€amplified colorectal cancer liver metastases in patients treated with <scp>HER2</scp>â€targeted therapy. <i>International Journal of Cancer</i> , 2020, 147, 3215-3223.	2.3	27
10	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 256-262.e2.	1.0	56
11	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. <i>Oncologist</i> , 2020, 25, 481-487.	1.9	77
12	Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102877.	2.0	14
13	Discovery of Ground-state Absorption Line Polarization and Sub-Gauss Magnetic Field in the Post-AGB Binary System 89 Her. <i>Astrophysical Journal Letters</i> , 2020, 902, L7.	3.0	8
14	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the â€BRAF BeCoolâ€™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	1.3	51
15	Quality of life assessment and reporting in colorectal cancer: a systematic review of phase 3 trials published between 2012 and 2018. <i>Annals of Oncology</i> , 2019, 30, iv29.	0.6	1
16	The first â€second solar spectrumâ€ ever observed in a star different than the sun: A highâ€resolution spectropolarimetric Atlas of 89 Herculis. <i>Astronomische Nachrichten</i> , 2019, 340, 409-412.	0.6	2
17	Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?. <i>Cancers</i> , 2019, 11, 1547.	1.7	10
18	Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2121-2137.	0.9	7

#	ARTICLE	IF	CITATIONS
19	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. <i>Clinical Colorectal Cancer</i> , 2019, 18, e394-e401.	1.0	13
20	Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience. <i>Cancers</i> , 2019, 11, 369.	1.7	4
21	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019, 111, 94-106.	1.3	36
22	Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine. <i>Cancers</i> , 2019, 11, 519.	1.7	21
23	Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients. <i>Cancers</i> , 2019, 11, 454.	1.7	4
24	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1395-1402.	1.9	95
25	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. <i>Journal of Geriatric Oncology</i> , 2019, 10, 591-597.	0.5	6
26	“Shades of Gray” in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 17-24.	2.0	3
27	Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18F-FDG PET and MRI radiomics features. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 878-888.	3.3	113
28	Emerging molecular target antagonists for the treatment of biliary tract cancer. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 63-75.	1.0	14
29	Bone metastases in biliary cancers: A multicenter retrospective survey. <i>Journal of Bone Oncology</i> , 2018, 12, 33-37.	1.0	5
30	Fluoropyrimidine-induced cardiotoxicity. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 124, 1-10.	2.0	44
31	Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e457-e470.	1.0	18
32	Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor. <i>International Journal of Cancer</i> , 2018, 143, 907-920.	2.3	41
33	Rationale for the use of metronomic chemotherapy in gastrointestinal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1451-1463.	0.9	5
34	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. <i>Cancer Cell</i> , 2018, 34, 148-162.e7.	7.7	129
35	Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma. <i>BMC Genomics</i> , 2018, 19, 440.	1.2	13
36	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000403.	2.0	20

#	ARTICLE	IF	CITATIONS
37	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , 2018, 95, 344-352.	0.9	11
38	SIFAP2: a new versatile configuration at the TNG for the MPPC based photometer. , 2018, , .		3
39	Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3506-3506.	0.8	8
40	Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. <i>PLoS ONE</i> , 2018, 13, e0191593.	1.1	12
41	Improvement of metastatic colorectal cancer patient survival: Single institution experience.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15633-e15633.	0.8	0
42	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 115, 1-12.	2.0	26
43	ZEEMAN DOPPLER MAPS: ALWAYS UNIQUE, NEVER SPURIOUS?. <i>Astrophysical Journal</i> , 2017, 834, 24.	1.6	8
44	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. <i>Gastric Cancer</i> , 2017, 20, 825-833.	2.7	32
45	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , 2017, 13, 2265-2275.	1.1	10
46	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , 2017, 22, 1463-1469.	1.9	27
47	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. <i>European Journal of Cancer</i> , 2017, 83, 106-115.	1.3	25
48	A Method to Measure the Transverse Magnetic Field and Orient the Rotational Axis of Stars. <i>Astrophysical Journal</i> , 2017, 848, 107.	1.6	11
49	Aflibercept efficacy according to sidedness, RAS and BRAF mutations. Findings from the VELOUR trial in second line therapy of advanced colorectal cancer patients. <i>Annals of Oncology</i> , 2017, 28, vi7.	0.6	3
50	Prognostic factors in unresectable biliary tract cancer: a GICO (Gruppo Italiano COlangiocarcinoma) retrospective analysis. <i>Annals of Oncology</i> , 2017, 28, vi48.	0.6	1
51	Real-world gastric cancer patients treated with at least three lines of chemotherapy: Outcomes and predictors for efficacy.. <i>Annals of Oncology</i> , 2017, 28, iii43-iii44.	0.6	0
52	Biliary tract carcinoma and chronic viral hepatitis in Italy: the GICO (Gruppo Italiano) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 142 Td (COLA	0.6	0
53	Survival of metastatic colorectal cancer patients at Candiolo Cancer Institute. <i>Annals of Oncology</i> , 2017, 28, vi11.	0.6	0
54	Second-line treatment efficacy in elderly vs. non-elderly advanced gastric cancer patients: an Italian multicentre real-world study. <i>Annals of Oncology</i> , 2017, 28, vi45.	0.6	0

#	ARTICLE	IF	CITATIONS
55	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. <i>Oncotarget</i> , 2016, 7, 69060-69074.	0.8	29
56	Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (VICTORIA-BILC study). <i>Cancer</i> , 2016, 122, 574-581.	2.0	121
57	Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 109-114.	1.1	10
58	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. <i>Targeted Oncology</i> , 2016, 11, 593-603.	1.7	14
59	Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. <i>BMC Cancer</i> , 2016, 16, 90.	1.1	35
60	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 738-746.	5.1	778
61	Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. <i>Oncologist</i> , 2016, 21, 600-607.	1.9	24
62	Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report. <i>BMC Cancer</i> , 2016, 16, 793.	1.1	8
63	Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. <i>Journal of Translational Medicine</i> , 2016, 14, 119.	1.8	18
64	Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. <i>Digestive and Liver Disease</i> , 2016, 48, 231-241.	0.4	74
65	Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient. <i>Tumor Biology</i> , 2016, 37, 4041-4052.	0.8	31
66	The HARPS-North@TNG polarimeter. , 2016, , .		2
67	HER2 amplification as a "molecular bait"™ for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS774-TPS774.	0.8	18
68	Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma. <i>Oncotarget</i> , 2016, 7, 52354-52363.	0.8	14
69	Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line. <i>Oncotarget</i> , 2016, 7, 86766-86780.	0.8	10
70	Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 156.	3.5	54
71	Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. <i>OncoTargets and Therapy</i> , 2015, 8, 1149.	1.0	5
72	Linifanib: current status and future potential in cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 677-687.	1.1	21

#	ARTICLE	IF	CITATIONS
73	Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy. <i>Chronobiology International</i> , 2015, 32, 1359-1366.	0.9	1
74	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. <i>Modern Pathology</i> , 2015, 28, 1481-1491.	2.9	226
75	Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3508-3508.	0.8	27
76	Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. <i>BMC Cancer</i> , 2014, 14, 918.	1.1	8
77	A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. <i>Annals of Oncology</i> , 2014, 25, 1750-1755.	0.6	164
78	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. <i>Annals of Oncology</i> , 2014, 25, 1373-1378.	0.6	84
79	Second-line chemotherapy in advanced biliary cancer: the present now will later be past. <i>Annals of Oncology</i> , 2014, 25, 2443-2444.	0.6	2
80	Screening for the <i>FGFR3</i> fusion in biliary tract carcinomas by nested PCR. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 1033-1040.	1.5	23
81	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. <i>British Journal of Cancer</i> , 2014, 110, 2165-2169.	2.9	69
82	Potentially resectable metastatic colorectal cancer: An individualized approach to conversion therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 218-226.	2.0	11
83	A polarimetric unit for HARPS-North at the Telescopio Nazionale Galileo: HANPO. <i>Proceedings of SPIE</i> , 2014, , .	0.8	2
84	SHARK (System for coronagraphy with High order Adaptive optics from R to K band): a proposal for the LBT 2nd generation instrumentation. <i>Proceedings of SPIE</i> , 2014, , .	0.8	3
85	Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer. <i>Cancer</i> , 2013, 119, 277-284.	2.0	72
86	Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. <i>Cancer</i> , 2013, 119, 3429-3435.	2.0	26
87	Biliary tract carcinomas: From chemotherapy to targeted therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 136-148.	2.0	39
88	Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS3648-TPS3648.	0.8	7
89	Targeted agents: how can we improve the outcome in biliary tract cancer?. <i>Hepatobiliary Surgery and Nutrition</i> , 2013, 2, 31-3.	0.7	4
90	Postoperative nomogram for predicting survival after resection for intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4129-4129.	0.8	1

#	ARTICLE	IF	CITATIONS
91	The Role of Lung Metastasis Resection in Improving Outcome of Colorectal Cancer Patients: Results From a Large Retrospective Study. <i>Oncologist</i> , 2012, 17, 1430-1438.	1.9	65
92	Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1528-1538.	1.9	14
93	Liver Metastases in Colon Cancer. , 2012, , 77-91.		1
94	NON-DETECTION OF MAGNETIC FIELDS IN THE CENTRAL STARS OF THE PLANETARY NEBULAE NGC 1360 AND LSS 1362. <i>Astrophysical Journal Letters</i> , 2011, 731, L33.	3.0	30
95	AURORAL RADIO EMISSION FROM STARS: THE CASE OF CU VIRGINIS. <i>Astrophysical Journal Letters</i> , 2011, 739, L10.	3.0	55
96	Adjuvant Chemotherapy and Follow-Up. <i>Updates in Surgery Series</i> , 2011, , 153-158.	0.0	0
97	Distress and quality of life after autologous stem cell transplantation: a randomized clinical trial to evaluate the outcome of a web-based stepped care intervention. <i>BMC Cancer</i> , 2010, 10, 361.	1.1	21
98	Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. <i>BMC Cancer</i> , 2010, 10, 631.	1.1	149
99	Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood and Marrow Transplantation Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 326-335.	2.0	27
100	Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab. <i>Anti-Cancer Drugs</i> , 2008, 19, 689-696.	0.7	7
101	Targeting of Epidermal Growth Factor Receptor in Patients Affected by Biliary Tract Carcinoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1145-1145.	0.8	6
102	Tumor Cell Purging by Ex Vivo Expansion of Hemopoietic Stem Cells from Breast Cancer Patients Combined with Targeting ErbB Receptors. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 68-74.	2.0	5
103	Outcome of Metastatic Colorectal Cancer: Analysis of a Consecutive Series of 229 Patients. The Impact of a Multidisciplinary Approach. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 1596-1601.	0.7	24
104	Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 1680-1685.	3.2	151
105	Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. <i>Journal of Leukocyte Biology</i> , 2003, 74, 593-601.	1.5	17
106	Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction. <i>Bone Marrow Transplantation</i> , 2001, 27, 517-523.	1.3	19
107	Epidemiological and virological analysis of couples infected with hepatitis C virus. <i>Gut</i> , 1999, 45, 112-116.	6.1	52
108	Hepatitis C virus (HCV) hypervariable region 1 complexity does not correlate with severity of liver disease, HCV type, viral load or duration of infection. <i>Journal of Hepatology</i> , 1998, 29, 689-694.	1.8	12

#	ARTICLE	IF	CITATIONS
109	Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. <i>Gastroenterology</i> , 1997, 113, 567-572.	0.6	142